Covered recipient · General Payments record
VIRGINIA G KAKLAMANI
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$155,979.62
125 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $91,434.96 | 29 |
| Consulting Fee | $40,623.00 | 11 |
| Travel and Lodging | $19,306.04 | 51 |
| Honoraria | $2,500.00 | 1 |
| Food and Beverage | $2,115.62 | 33 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $41,257.57 | 31 |
| Celgene Corporation | $34,318.40 | 21 |
| PFIZER INC. | $32,947.94 | 19 |
| Puma Biotechnology, Inc. | $26,209.13 | 26 |
| Genentech USA, Inc. | $7,457.57 | 4 |
| PFIZER INTERNATIONAL LLC | $5,139.52 | 5 |
| Sirtex Medical Inc | $3,348.36 | 3 |
| EISAI INC. | $2,542.01 | 3 |
| F. Hoffmann-La Roche AG | $1,854.96 | 2 |
| AstraZeneca Pharmaceuticals LP | $852.77 | 8 |
| Lilly USA, LLC | $32.25 | 2 |
| Amgen Inc. | $19.14 | 1 |
Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
VIRGINIA G KAKLAMANI
NPI 1841235439 · CMS profile ID 129081
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
SAN ANTONIO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1841235439?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- VIRGINIA G KAKLAMANI, NPI 1841235439, CMS profile ID 129081. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841235439?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). VIRGINIA G KAKLAMANI, NPI 1841235439, CMS profile ID 129081. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841235439?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- VIRGINIA G KAKLAMANI, NPI 1841235439, CMS profile ID 129081, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1841235439?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
125 matching records · $155,979.62 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–125 of 125.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $14.58 | 03/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658212301 | CMS |
| Puma Biotechnology, Inc. | $4,500.00 | 03/21/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706020995 | CMS |
| Celgene Corporation | $347.63 | 03/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672758219 | CMS |
| Puma Biotechnology, Inc. | $65.00 | 03/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706020959 | CMS |
| Puma Biotechnology, Inc. | $271.16 | 03/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706020961 | CMS |
| EISAI INC. | $2,500.00 | 02/26/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697046077 | CMS |
| Celgene Corporation | $502.74 | 02/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672736117 | CMS |
| Celgene Corporation | $61.66 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672781275 | CMS |
| Puma Biotechnology, Inc. | $164.55 | 02/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706020955 | CMS |
| Puma Biotechnology, Inc. | $164.55 | 02/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706020957 | CMS |
| Puma Biotechnology, Inc. | $108.23 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706020953 | CMS |
| Puma Biotechnology, Inc. | $4,500.00 | 02/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706020951 | CMS |
| Novartis Pharmaceuticals Corporation | $1,160.00 | 02/06/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659720415 | CMS |
| Celgene Corporation | $132.28 | 02/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672718821 | CMS |
| Celgene Corporation | $7,450.00 | 02/02/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672719453 | CMS |
| Celgene Corporation | $293.80 | 02/02/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672719623 | CMS |
| Celgene Corporation | $206.30 | 02/02/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672997851 | CMS |
| Celgene Corporation | $176.98 | 02/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672736400 | CMS |
| Puma Biotechnology, Inc. | $278.60 | 01/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706020963 | CMS |
| Puma Biotechnology, Inc. | $55.00 | 01/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706020965 | CMS |
| Novartis Pharmaceuticals Corporation | $245.92 | 01/24/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659720417 | CMS |
| Novartis Pharmaceuticals Corporation | $3,480.00 | 01/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659720419 | CMS |
| Novartis Pharmaceuticals Corporation | $49.48 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659720421 | CMS |
| PFIZER INTERNATIONAL LLC | $3,750.00 | 01/08/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672215713 | CMS |
| PFIZER INTERNATIONAL LLC | $1,063.00 | 01/08/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672989087 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $222.80 | 1 |
| PY2025 | Principal investigator | $686,601.57 | 69 |
| PY2024 | Recipient | $3,448.00 | 1 |
| PY2024 | Principal investigator | $395,361.60 | 42 |
| PY2023 | Recipient | $724.26 | 1 |
| PY2023 | Principal investigator | $453,549.50 | 56 |
| PY2022 | Recipient | $2,422.00 | 2 |
| PY2022 | Principal investigator | $222,988.94 | 33 |
| PY2021 | Recipient | $1,794.03 | 7 |
| PY2021 | Principal investigator | $898,860.32 | 79 |
| PY2020 | Principal investigator | $1,138,811.01 | 103 |
| PY2019 | Principal investigator | $886,149.35 | 212 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
70 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $2,872.00 | 12/31/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670992 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $899.94 | 12/31/2025 | Non-covered Recipient Entity Mays Cancer Center | A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors | No dispute reported | 06/30/2026 | 1232930073 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $407.00 | 12/12/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386780 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $407.00 | 12/12/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386782 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $421.00 | 12/12/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386784 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $78.60 | 12/12/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386786 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $407.00 | 12/12/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386788 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $407.00 | 12/12/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386790 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $407.00 | 12/12/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386792 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $421.00 | 12/12/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386796 |
| Principal investigator 1 | Genentech, Inc. | $2,653.20 | 12/03/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670989 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,500.00 | 11/03/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386794 |
| Principal investigator 1 | Genentech, Inc. | $3,976.00 | 10/30/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670981 |
| Principal investigator 1 | Genentech, Inc. | $1,500.00 | 10/28/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670978 |
| Principal investigator 1 | Genentech, Inc. | $1,326.60 | 10/28/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670985 |
| Principal investigator 1 | Genentech, Inc. | $1,736.00 | 10/27/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679321 |
| Principal investigator 1 | Genentech, Inc. | $3,472.00 | 10/17/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679319 |
| Principal investigator 1 | Genentech, Inc. | $701.00 | 10/16/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679317 |
| Principal investigator 1 | BioNTech SE | $1,000.00 | 10/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | BNT327 | No dispute reported | 06/30/2026 | 1249017400 |
| Principal investigator 1 | BioNTech SE | $1,800.00 | 10/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | BNT327 | No dispute reported | 06/30/2026 | 1249017402 |
| Principal investigator 1 | BioNTech SE | $500.00 | 10/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | BNT327 | No dispute reported | 06/30/2026 | 1249017404 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $9,000.00 | 10/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136161 |
| Principal investigator 1 | Genentech, Inc. | $5,306.40 | 10/02/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670974 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 09/24/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679313 |
| Principal investigator 1 | Genentech, Inc. | $840.00 | 09/24/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679315 |
| Principal investigator 1 | Genentech, Inc. | $2,280.00 | 09/08/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679311 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $70.00 | 09/01/2025 | Non-covered Recipient Entity UT HEALTH SAN ANTONIO MAYS CANCER CENTER | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136793 |
| Principal investigator 1 | Genentech, Inc. | $6,958.00 | 08/25/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670966 |
| Principal investigator 1 | Genentech, Inc. | $935.00 | 08/01/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679305 |
| Principal investigator 1 | Genentech, Inc. | $4,690.00 | 07/29/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679303 |
| Principal investigator 1 | Genentech, Inc. | $9,286.20 | 07/22/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670970 |
| Principal investigator 1 | Genentech, Inc. | $14,070.00 | 07/10/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679309 |
| Recipient | Novartis Pharmaceuticals Corporation | $222.80 | 07/09/2025 | Covered Recipient Physician | CLEE011A2301,CLEE011E2301,CLEE011F2301 | No dispute reported | 06/30/2026 | 1190291961 |
| Principal investigator 1 | Genentech, Inc. | $5,208.00 | 07/03/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679307 |
| Principal investigator 1 | Genentech, Inc. | $1,120.00 | 07/02/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679293 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $2,500.00 | 06/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136129 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $26,000.00 | 06/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136135 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $750.00 | 06/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136139 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $2,500.00 | 06/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136144 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $4,000.00 | 06/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136148 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $250.00 | 06/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136152 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,000.00 | 06/27/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136157 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $401.00 | 06/24/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386798 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,718.00 | 06/24/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386800 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $421.00 | 06/24/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $407.00 | 06/24/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386804 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $407.00 | 06/24/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386806 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $407.00 | 06/24/2025 | Non-covered Recipient Entity University Of Texas Health Science Center At San Antonio | DS8201-A-U302 | No dispute reported | 06/30/2026 | 1223386808 |
| Principal investigator 1 | Genentech, Inc. | $24,960.00 | 06/05/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679289 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $143.64 | 05/23/2025 | Non-covered Recipient Entity UT HEALTH SAN ANTONIO MAYS CANCER CENTER | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136789 |
| Principal investigator 1 | Genentech, Inc. | $18,760.00 | 05/21/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679291 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $94.69 | 05/12/2025 | Non-covered Recipient Entity UT HEALTH SAN ANTONIO MAYS CANCER CENTER | A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer | No dispute reported | 06/30/2026 | 1244136786 |
| Principal investigator 1 | Genentech, Inc. | $1,857.00 | 04/21/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670958 |
| Principal investigator 1 | Genentech, Inc. | $5,688.00 | 04/16/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679301 |
| Principal investigator 1 | Genentech, Inc. | $30,299.00 | 04/09/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679297 |
| Principal investigator 1 | Genentech, Inc. | $3,979.80 | 04/04/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670962 |
| Principal investigator 1 | Genentech, Inc. | $3,095.00 | 03/25/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670954 |
| Principal investigator 1 | Genentech, Inc. | $5,773.00 | 03/20/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679299 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $35,500.00 | 03/17/2025 | Non-covered Recipient Entity Mays Cancer Center | A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous E | No dispute reported | 06/30/2026 | 1232934766 |
| Principal investigator 1 | Eli Lilly and Company | $60.05 | 03/10/2025 | Non-covered Recipient Entity UNIV OF TX HEALTH SCIENCES CENTER AT SAN ANTONIO | POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 1187892054 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $750.00 | 03/03/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | SOLAR1 A phase III randomized double blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer which progressed on or after aromatase in | No dispute reported | 06/30/2026 | 1190307423 |
| Principal investigator 1 | Eisai Inc. | $42,524.56 | 02/26/2025 | Non-covered Recipient Entity University Of Texas Health Science | Phase II trial of eribulin and lenvatinib in advanced solid tumors | No dispute reported | 06/30/2026 | 1244561983 |
| Principal investigator 1 | Genentech, Inc. | $912.00 | 02/20/2025 | Non-covered Recipient Entity UNIVERSITY OF TEXAS HEALTH SCIENCE CTR FINANCIAL AFFAIRS MANAGER | T DM1 Atezolizumab in high risk HER2 patients with residual disease | No dispute reported | 06/30/2026 | 1211679295 |
| Principal investigator 1 | BioNTech SE | $4,500.00 | 02/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | BNT327-02 | No dispute reported | 06/30/2026 | 1249017338 |
| Principal investigator 1 | BioNTech SE | $4,000.00 | 02/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | BNT327-02 | No dispute reported | 06/30/2026 | 1249017340 |
| Principal investigator 1 | BioNTech SE | $20,000.00 | 02/05/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | BNT327-02 | No dispute reported | 06/30/2026 | 1249017342 |
| Principal investigator 1 | Genentech, Inc. | $6,633.00 | 01/17/2025 | Non-covered Recipient Entity The University of Texas Health Science Center at San Antonio | An open label multicenter extension study | No dispute reported | 06/30/2026 | 1211670950 |
| Principal investigator 1 | Eli Lilly and Company | $25,693.00 | 01/13/2025 | Non-covered Recipient Entity UNIV OF TX HEALTH SCIENCES CENTER AT SAN ANTONIO | POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | No dispute reported | 06/30/2026 | 1187891652 |
| Principal investigator 1 | Eli Lilly and Company | $3,289.89 | 01/09/2025 | Non-covered Recipient Entity UNIV OF TX HEALTH SCIENCES CENTER AT SAN ANTONIO | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187891834 |
| Principal investigator 1 | Eli Lilly and Company | $317,172.00 | 01/06/2025 | Non-covered Recipient Entity UNIV OF TX HEALTH SCIENCES CENTER AT SAN ANTONIO | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187892050 |